Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma : a retrospective, multicenter study
© 2023. The Author(s)..
AIMS: To investigate the predictive value of baseline C-reactive protein (CRP) levels on the efficacy of chemotherapy plus immune checkpoint inhibitors (ICI) in patients with advanced lung squamous cell carcinoma (LSCC).
MATERIALS AND METHODS: In this retrospective multicenter study spanning from January 2016 to December 2020, advanced LSCC patients initially treated with chemotherapy or a combination of chemotherapy and ICI were categorized into normal and elevated CRP subgroups. The relationship between CRP levels and treatment outcomes was analyzed using multivariate Cox proportional hazards models and multivariate logistic regression, focusing primarily on the progression-free survival (PFS) endpoint, and secondarily on overall survival (OS) and objective response rate (ORR) endpoints. Survival curves were generated using the Kaplan-Meier method, with the log-rank test used for comparison between groups.
RESULTS: Of the 245 patients evaluated, the 105 who received a combination of chemotherapy and ICI with elevated baseline CRP levels exhibited a significant reduction in PFS (median 6.5 months vs. 11.8 months, HR, 1.78; 95% CI: 1.12-2.81; p = 0.013) compared to those with normal CRP levels. Elevated CRP was identified as an independent risk factor for poor PFS through multivariate-adjusted analysis. However, among the 140 patients receiving chemotherapy alone, baseline CRP levels did not significantly influence PFS. Furthermore, within the combination therapy group, there was a notable decrease in the ORR (51% vs. 71%, p = 0.035), coupled with a significantly shorter OS (median 20.9 months vs. 31.5 months, HR, 2.24; 95% CI: 1.13-4.44; p = 0.033).
CONCLUSION: In patients with advanced LSCC, elevated baseline CRP levels were identified as an independent predictive factor for the efficacy of combination therapy with chemotherapy and ICI, but not in chemotherapy alone. This suggests that CRP may be a valuable biomarker for guiding treatment strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC cancer - 23(2023), 1 vom: 16. Dez., Seite 1244 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheng, Xinlong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 19.12.2023 Date Revised 19.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-023-11737-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365947997 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365947997 | ||
| 003 | DE-627 | ||
| 005 | 20231227134518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-023-11737-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1232.xml |
| 035 | |a (DE-627)NLM365947997 | ||
| 035 | |a (NLM)38104105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheng, Xinlong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma |b a retrospective, multicenter study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.12.2023 | ||
| 500 | |a Date Revised 19.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a AIMS: To investigate the predictive value of baseline C-reactive protein (CRP) levels on the efficacy of chemotherapy plus immune checkpoint inhibitors (ICI) in patients with advanced lung squamous cell carcinoma (LSCC) | ||
| 520 | |a MATERIALS AND METHODS: In this retrospective multicenter study spanning from January 2016 to December 2020, advanced LSCC patients initially treated with chemotherapy or a combination of chemotherapy and ICI were categorized into normal and elevated CRP subgroups. The relationship between CRP levels and treatment outcomes was analyzed using multivariate Cox proportional hazards models and multivariate logistic regression, focusing primarily on the progression-free survival (PFS) endpoint, and secondarily on overall survival (OS) and objective response rate (ORR) endpoints. Survival curves were generated using the Kaplan-Meier method, with the log-rank test used for comparison between groups | ||
| 520 | |a RESULTS: Of the 245 patients evaluated, the 105 who received a combination of chemotherapy and ICI with elevated baseline CRP levels exhibited a significant reduction in PFS (median 6.5 months vs. 11.8 months, HR, 1.78; 95% CI: 1.12-2.81; p = 0.013) compared to those with normal CRP levels. Elevated CRP was identified as an independent risk factor for poor PFS through multivariate-adjusted analysis. However, among the 140 patients receiving chemotherapy alone, baseline CRP levels did not significantly influence PFS. Furthermore, within the combination therapy group, there was a notable decrease in the ORR (51% vs. 71%, p = 0.035), coupled with a significantly shorter OS (median 20.9 months vs. 31.5 months, HR, 2.24; 95% CI: 1.13-4.44; p = 0.033) | ||
| 520 | |a CONCLUSION: In patients with advanced LSCC, elevated baseline CRP levels were identified as an independent predictive factor for the efficacy of combination therapy with chemotherapy and ICI, but not in chemotherapy alone. This suggests that CRP may be a valuable biomarker for guiding treatment strategies | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C-reactive protein | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Lung squamous cell carcinoma | |
| 650 | 4 | |a Predictive biomarker | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Zhang, Longfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jianguo |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yihong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zhenzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lijin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Meijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhenhua |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhijie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Huijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Zhengbo |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Anwen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Zhengbo |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shengchi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Chenzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Chunwei |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Dingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xiaobin |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Kan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yiquan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Haibo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qiuyu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Shanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yujing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Sihui |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Gen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 23(2023), 1 vom: 16. Dez., Seite 1244 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:16 |g month:12 |g pages:1244 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-023-11737-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 16 |c 12 |h 1244 | ||